Organisation paid for research Program year 2025 Source: CMS Open Payments

Central Texas Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,952,124

125 payments

Through program year 2025, Central Texas Clinical Research is reported as receiving $2,952,124 in research payments, across 125 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$85,767	14
2024	Research	$143,024	7
2023	Research	$447,628	31
2022	Research	$611,772	14
2021	Research	$1,354,621	24
2020	Research	$293,121	32
2019	Research	$16,192	3

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $1,921,483 9 payments
ViiV Healthcare Company $632,923 62 payments
Exeltis, USA Inc. $212,761 27 payments
AbbVie, Inc. $141,563 19 payments
Amgen Inc. $24,201 4 payments
Janssen Research & Development, LLC $19,195 4 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender Women Who Have Sex With Men, and Are at High Risk for HIV-1 Infection $1,754,464 5 payments
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women $199,781 20 payments
A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority $194,103 7 payments
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL 100 mg,0.25 mg Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF $156,687 2 payments
PH 3 HIV Two-Year Non-Inferiority Compared to Standard of Care Safety/ $139,491 10 payments
Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1) $103,793 15 payments
A Phase Iib, Multicenter, Open-Label, Rollover Study Evaluating the Ef $98,113 8 payments
A Phase Iib Study Evaluating A Long-Acting Intramuscular Regimen of GS $72,167 10 payments
A Phase 2B Multicenter, Randomized, Open-Label Study Comparing the Eff $68,925 12 payments
A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority $27,302 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.